Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition
{{output}}
Background Mammalian Target of Rapamycin Complex 1 (mTORC1) inhibitors enhance chemotherapy response in acute myelogenous leukemia (AML) cells in vitro. However whether inhibiting mTORC1 enhances clinical response to AML chemotherapy remains controversial. We ... ...
